Clinical application and research progress of atomization inhalation therapy
LEI Ting-ting;ZHAO Rong-sheng;Department of Pharmacy;Peking University Third Hospital;China Pharmaceutical University;

..............page:1-5

Research progress on pathophysiology of hypersensitivity reactions induced by iodinated contrast media and relative prevention and treatment approaches
LIANG Yao;SUN Lu-lu;Department of Pharmacy;Beijing Shijitan Hospital to Capital Medical University;Department of Pharmacy Administration and Clinical Pharmacy;School of Pharmaceutical Sciences;Peking University Health Science Center;

..............page:6-10

Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer
HU Xing-sheng;LI Jun-ling;LI Yi-qun;WANG Yan;HAO Xue-zhi;LIU Yu-tao;SHI Yuan-kai;Department of Medical Oncology;Cancer Hospital;Chinese Academy of Medical Sciences;Peking Union Medical College;

..............page:11-15

Evidence-based evaluation of proton pump inhibitors off-label use
LI Hui-bo;ZHANG Chao;DING Shi-gang;ZHAO Rong-sheng;Pharmacy Department;Peking University Third Hospital;Gastroenterology Department;Peking University Third Hospital;

..............page:15-19

Analysis of clinical features and treatment efficacy in patients with BRAF mutated colorectal carcinoma
LI Juan;HAN Chun;WANG Yi-shang;BAI Li;Department of Oncology;Chinese PLA General Hospital;

..............page:20-24

Computational simulation of active ingredients and its mechanism of cardiac effect in Qili Qiangxin capsules
ZHANG Bi-hua;JIN Yi;YANG Ming;YANG Li-ping;Department of Pharmacy;Beijing Hospital;Ministry of Public Health;Shenyang Pharmaceutical University;

..............page:25-32

Clinical efficacy and safety of Aluminium and Magnesium suspension for the treatment of gastric acid-related symptoms
YAN Yao-dong;WEN Quan;DONG Hong-hong;YANG Zhong-min;Affiliated Hospital of institute of Aviation Medicine Air Force;Air Force Logistics College;Beijing Qingrui Pharmaceutical technology development Co.;Ltd;

..............page:33-36

Clinical efficacy of Supervising the Usage Method of Budesonide and Formoterol Fumarate Powder for Inhalation for the treatment of patients with bronchial asthma
LIU Xiao-liang;CAO Li-qiang;SHEN Na;Department of Pharmacy;Jiangyin Hospital Affiliated to Medical College of Southeast University;Department of Respiration Medicine;Jiangyin Hospital Affiliated to Medical College of Southeast University;

..............page:36-39

Investigation of drug use in patients with hypertension in remote mountainous countryside of Beijing
LIU Jian-hua;DU Juan;Department of Pharmacy;Beijing Changping TCM Medicine Hospital;

..............page:40-43

Correlation between cerebral infarction and plasma homocysteine levels in young and middle-aged patients with silent cerebral infarction
YAO Dong-mei;LI Zhen-liang;YAO Gui-lan;Department of Neurosurgery;Tangshan Ninth Hospital;Department of Brain section Ⅰ;Tangshan Ninth Hospital;Department of Brain section Ⅱ;Tangshan Ninth Hospital;

..............page:44-46

Investigation on the cognition and behavior of medical personnel on the cytotoxic drug overflow and protection
YUAN Si-si;FENG Xin;HOU Xin-mei;LIU Lu-lu;LIU Xin-shuo;Department of Pharmacy;Beijing Obstetrics and Gynecology Hospital;Capital Medical University;

..............page:47-49

Evaluation of the effect of community pharmaceutical care intervention in essential hypertension patients
SONG Jian-min;ZHANG Shuang;GONG Xue;WAN Di;Departemet of Pharmacy;xicheng zhanlanlu Hospital of Bejing;

..............page:50-52

Prolonged QT Interval and Ventricular Fibrillation Induced by Digoxin: Pooled Analysis of 7 Cases
HU Yang;DING Jian-jie;MEI Dan;ZHANG Bo;Department of Pharmacy;Peking Union Medical College Hospital;Chinese Academy of Medical Science;Department of Clinical Pharmacy;Xingyang People’s Hospital;

..............page:53-56

Analysis on medication rationality of teicoplanin in clinical practices
ZHAO Ming;LIANG Liang;JI Li-wei;ZHANG Ya-tong;CHEN Di;ZHU Yuan-chao;Department of Pharmacy;Beijing Hospital;Beijing Key Laboratory of Assessment of Clinical Drug Risk and Individualized Application;National Clinical Research Center of Respiratory Diseases;

..............page:57-60

Literatures analysis of adverse drug reactions induced by ceftriaxone with negative skin test
ZHAO Shan-shan;LI Jing;Department of Pharmacy;China Meitan General Hospital;

..............page:60-63

Analysis on the role of statins in the early-stage treatment of acute respiratory failure patients
WU Da-yong;ZHU Dong;ZHANG Li-qun;Shaoxing Hospital of China Medical University;

..............page:64-66

Cost-effective analysis of two different kinds of common macrolide antibiotics for the treatment of children with mycoplasma pneumonia
ZHU Mei;WU Hui-lan;Taizhou Hospital zhejiang Province;

..............page:67-69

A case analysis on skin rash caused by salmeterol/ fluticasone propionate
LIU Xiao-hui;FENG Xue-li;ZHAO Li-bo;WANG Xiao-ling;Xu Bao-ping;Department of Pharmacy;Beijing Children’s Hospital;Capital Medical University;Department of Respiration;Beijing Children’s Hospital;Capital Medical University;

..............page:70-72

Pharmaceutical carefor one patient with ventilator-associated pneumonia by the clinical pharmacist
GU Yuan-yuan;GONG Ying;HE Ting;HUA Guo-dong;Dongfang Hospital Affiliated to Beijing University of Traditional Chinese Medicine;

..............page:72-75

Risk Factors Analysis and Pharmaceutical Care on One Case with Nephrotic Syndrome and Glucocorticoid-induced Osteonecrosis
PAN Yu-hua;LAO Hai-yan;WANG Xiao-xing;TANG Kun;Department of Pharmacy;Guangdong General Hospital;Guangzhou Academy of Medical Sciences;Department of Pharmacy;China-Japan Friendship Hospital;

..............page:76-80

Pharmaceutical care on patients with cardiac insufficiency at the end stage and multiple serous cavity effusion: A case report
WU Qian;ZHANG Ya-tong;SHI Ai-xin;College of life science and biotechnology;Shenyang Pharmaceutical University;Pharmacy Departemnt;Beijing Hospital;

..............page:81-83

A new drug for the treatment of genotype 4 hepatitis C without interferon-Technivie
LUO Xiang;ZHONG Wu;National Engineering Research Center for the Strategic Drug;Institute of Pharmacology & Toxicology of AMMS;

..............page:84-88

shu zi yong fa

..............page:88

er xing tang niao bing huan zhe :dpp-4 yi zhi ji shi fou dao zhi xin shuai feng xian zeng jia
li zuo zuo ;

..............page:89

er tong yu cheng ren jie zhong yi miao hou fa sheng yan zhong guo min fan ying de feng xian
li zuo zuo ;

..............page:89-90

chi xu shu zhu yu chuan tong jian duan shu zhu zuo la xi lin / ta zuo ba tan zai zhi liao tong lv jia dan bao jun gan ran zhong de an quan xing ji you xiao xing xiang dang
ying ying qiu ;

..............page:90

ba xiang kang zhong liu xin ji shu kang ti ou lian yao wu
zhou xin bo ; li jing ;

..............page:91-92